Kornimate/medical-research-clean huggingface dataset:
trevo aspiration proximal flow control registry

Conditions: Stroke, Ischemic

Summary: this purpose of this retrospective, single-arm, non-randomized, multi-center study is to collect real-world data on the effectiveness of using the trap technique in acute ischemic stroke patients undergoing mechanical thrombectomy.

the trap registry is designed to collect real-world data on the use of the trap technique for mechanical thrombectomy in stroke patients. recanalization success (as assessed using a tici score), along with the time to recanalization and number of passes needed for success will be assessed at the conclusion of the procedure. in addition, neurologic recovery (as evaluated using the modified rankin scale and national institutes of health score) will be assessed at 24 hours, discharge, and 90 days after the thrombectomy procedure.

Eligibility criteria:
inclusion criteria: * subject experiencing an acute ischemic stroke in which imaging demonstrates a vascular occlusion located in the distal internal carotid artery (ica) through the distal middle cerebral artery (mca) * subjects in which the trap technique is used for at least the first two thrombectomy passes per occluded vessel * subjects that range in age from 18-85 * subjects with a prestroke modified rankin scale of 0-1 and presenting with an nihss of 8-30 * subjects that the operator feels may be treated with endovascular therapy * subjects in which computed tomography (ct)/magnetic resonance imaging (mri) demonstrates an infarct size of less than 70cc on mri or alberta stroke program early ct (aspects) score overall of 6 or better * subjects in which groin puncture can be obtained within 6 hours of symptom onset (with or without total plasminogen activator administration) * subjects who have consented in accordance with local institutional review board requirements exclusion criteria: * absence of large vessel occlusion on neuroimaging * evidence of tandem occlusion on neuroimaging * platelet count \< 100 x 10³ cells/mm³ or known platelet dysfunction * contraindication to ct and/or mri (i.e., due to contrast allergy or prior implant that precludes mri imaging) * previously documented contrast allergy that is not amenable to medical treatment * women who are pregnant or breastfeeding at time of intervention * evidence of brain hemorrhage on ct and/or mri at presenting hospital
impact of body mass index on positive end-expiratory pressure guided by electrical impedance tomography for patients under general anaesthesia

Conditions: General Anesthetic; Positive Expiratory Pressure; Obesity

Summary: the induction of general anaesthesia is associated with a fall in lung volume due in particular to a decrease in muscle tone and the formation of denitrogenation atelectasis. many recent studies insist on the need to apply a so-called "protective" strategy of intraoperative ventilation, which combines the use of recruitment manoeuvres, reduced tidal volume (vt) (6-8ml/kg) and positive expiratory pressure (peep) to prevent these phenomena. however, the setting of peep remains debated and several authors agree on the need to individualize ventilatory parameters, particularly in obese patients, without describing the individualization tools. in the icu, it has been shown that electrical impedance tomography (eit) can be used to individualise the peep level in a simple and non-invasive way. therefore, we wish to determine whether the use of this technique during general anaesthesia allows for the individualization of peep, and whether the value determined is correlated with the body mass index (bmi).


Eligibility criteria:
inclusion criteria: * adult patient * patient who received general anesthesia with orotracheal intubation. * patient who has undergone surgery of the following types: : abdominal surgery by laparotomy or laparoscopy, emergency or scheduled exclusion criteria: * na
viral infection of hspc impacts hematopoiesis

Conditions: HIV-1; SARS-CoV-2

Summary: we propose to demonstrate that hiv-1 and sars-cov-2 are capable of targeting long-lived hspc with self-renewal capacities. these progenitors, thus transformed into host cells, can give rise to a durable source of infected cells with an impact on hematopoiesis.

virus-induced immunosuppression is the transient or persistent decline of immune cell counts and/or function caused by a virus, favouring its persistence in the host organisms. when sustained, triggered by acute viral replication or maintained by chronic viral infections, virus-induced immunosuppression is a life-threatening condition. it is notoriously observed in chronic hiv-1 infection and even in a considerable fraction of antiretroviral-treated hiv-infected individuals. it is also observed in some individuals recovering from severe and mild-to-moderate covid-19. its mechanisms are elusive and efficient therapeutic options are not available. virus-induced immunosuppression may occur in the periphery (affecting circulating immune cells) or in the bone marrow, affecting hematopoietic stem and progenitor cells (hspc) and hematopoiesis. several viruses can infect hspcs. hiv-1 can directly infect hsc, negatively impacting hsc function and the whole stem cell environment of the bone marrow. whether hsc can be productively infected by sars-cov-2 or just targeted and modulated by it remains uncertain and further studies are required to determine hspc susceptibility or viral sensing for sars-cov-2. therefore, we will i) evaluate which hematopoietic stem and progenitor cells (hspc) are targeted by hiv-1 (in vivo and ex vivo) and sars-cov-2 (ex vivo); ii) evaluate whether these infected hspc would modulate the bone marrow environment by upregulating inflammatory cytokines detrimental to lymphopoiesis.

Eligibility criteria:
inclusion criteria: hiv patients : * hiv-positive patients with a negative or positive viral load. * managed at ambroise paré hospital. * patients with a bone marrow biopsy or myelogram performed as part of their care. healthy subjects without hiv - patients with a bm biopsy or myelogram performed as part of their care for a suspected hematological pathology. management at ambroise paré hospital. exclusion criteria: -

Keywords: hiv-1 sars-cov-2 hematopoietic progenitors virus-induced immunosuppression
effects of a clinical pharmacist service on health-related quality of life

Conditions: Quality of Life

Summary: the aim of the present study is to evaluate effects of a clinical pharmacist service on health-related quality of life and prescribing of drugs.

a randomized controlled trial is performed in two internal medicine wards at sahlgrenska university hospital, göteborg, sweden.

Eligibility criteria:
inclusion criteria: * all patients admitted to the wards during week days after decision of a ward physician or nurse if the medical condition allows inclusion exclusion criteria: * exclusion criteria are poor swedish language and planned discharge before the intervention can be performed. * patients transferred to wards not belonging to the department of medicine or other hospitals during the hospital stay are also excluded.
treatment for subjects with chronic kidney disease receiving haemodialysis

Conditions: Kidney Disease

Summary: treatment period 1:to demonstrate that switching hd subjects with a baseline haemoglobin (hb) ≥ 10 g/dl and ≤ 13 g/dl from either subcutaneous (sc) or intravenous (iv) rhuepo to iv darbepoetin alfa results in a mean hb \> 11 g/dl. treatment period 2:to demonstrate that switching subjects with a hb \> 11 g/dl and ≤ 13 g/dl from once weekly iv darbepoetin alfa to once every 2 weeks (q2w) maintains the mean hb at \> 11 g/dl.


Eligibility criteria:
inclusion criteria: -at least 18 years old - diagnosis of chronic kidney disease (ckd) and receiving dialysis for at least 3 months prior to screening - baseline hb level greater than or equal to 10.0 g/dl and less than or equal to 13.0 g/dl - adequate iron stores (defined as serum ferritin greater than or equal to 100 µg/l or transferrin saturation \[tsat\] greater than or equal to 20%) - stable iv (epoetin alfa or beta) or sc rhuepo (epoetin beta) therapy 2 or 3 times per week for at least 8 weeks before screening (stable is defined as less than 25% change in weekly dose and no change in frequency or route) - all subjects must practice adequate contraception (in the judgment of the investigator) throughout this trial. exclusion criteria: - received sc epoetin alfa in the 12 months before screening - uncontrolled hypertension (diastolic blood pressure greater than 100 mmhg or systolic blood pressure greater than 180 mmhg on 2 separate occasions during screening) - prior history (within 12 weeks before enrolment) of cardiovascular events including: * acute myocardial ischemia; * hospitalization for congestive heart failure; * myocardial infarction. - pregnant or breast-feeding women - treatment with an investigational agent or device within 30 days before screening or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study - known sensitivity to any of the products to be administered during dosing - disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures

Keywords: chronic kidney disease (ckd) haemoglobin (hb) erthropoetin (epo) end stage renal disease (esrd) recombinant human erthropoetic (rhuepo) anaemia darbepoetin alfa, aranesp® haemodialysis clinical trial
effects of normobaric hypoxia and different exercise modes on blood glucose regulation in overweight adults

Conditions: Overweight; Healthy; Physical Inactivity

Summary: obesity is a major global health issue and a primary risk factor for metabolic-related disorders. while physical inactivity is one of the main contributors to obesity, it is a modifiable risk factor with exercise training as an established, non-pharmacological treatment to prevent the onset of metabolic-related disorders, including obesity. exposure to low-oxygen availability (hypoxia) via normobaric hypoxia (simulated altitude via reduced inspired oxygen fraction), termed hypoxic conditioning, in combination with exercise has been increasingly shown in the last decade to enhance blood glucose regulation and decrease body mass index, providing a feasible strategy to treat obesity. however, findings from studies investigating the potential for hypoxia to augment the exercise training response and subsequent metabolic health are equivocal. notably, there is a lack of information regarding the optimal combination of exercise variables and hypoxic severity to enable an individualized and safe practice of exercising in a hypoxic environment. in the present randomized, single-blind, cross-over study, the investigators will investigate the effects of single-bout of different exercise modes under moderate hypoxia (fio2, 16.5%). the investigators hypothesize that all exercises combined with hypoxia improve glucose homeostasis in overweight individuals.

in the present randomized, single-blind, cross-over study, participants will be exposed to moderate hypoxia (oxygen level 16.5%) during three different exercises (low-intensity cycling, sprint interval and functional exercises). participants will be randomly assigned to each exercise condition (computer-generated randomization plan), separated by a washout period (5-7 days). to accomplish this, participants will exercise in an environmental chamber in which oxygen concentration of the ambient air and, as such, oxygen levels can be closely controlled and monitored. participants are required to attend the laboratory 8 times. these visits are including pre-exercise screening, baseline blood sampling, body composition screening and exercise in altitude conditions.

Eligibility criteria:
inclusion criteria: * bmi is between 25-29 kg/m² * physical inactive (physical activity \<150 min/week) * no known heart or metabolic diseases (such as type 2 diabetes) * not currently taking any prescribed medication * no reported musculoskeletal injuries recently * not exposed to hypoxia \>1000 m prior to the study exclusion criteria: * impaired glucose tolerance (2 hour glucose: \>7.8 - 11.1 mmol/l) * type 2 diabetes mellitus * obstructive sleep apnea * chronic obstructive pulmonary disease
concentrations of salmeterol in blood and urine

Conditions: Asthma

Summary: the purpose of the study is to assess the blood and urine concentrations of inhaled salmeterol.

the purpose of the study is to assess the serum and urine concentrations of salmeterol after inhalation of 100 microgram salmeterol in one dose. furthermore, to evaluate any difference in three groups: 10 healthy men, 10 male asthmatic subjects and 10 male elite athletes with asthma.

Eligibility criteria:
inclusion criteria: * physician-diagnosed asthma with positive reversibility or challenge test. * informed consent. * age between 18-45 years. * sex: male. * asthma classified as mild to moderate according to gina guidelines. * used beta-2-agonist in minimum 12 months. exclusion criteria: * smokers or ex-smokers with a smoking history of 10 pack years or more. * respiratory tract infections within the last 2 weeks prior to study day. * subjects with other chronic diseases than asthma and/or allergy. * allergy towards the study medicine. * use of beta-2-agonist 10 days prior to study day.

Keywords: asthma doping salmeterol beta-agonist urine concentrations
vitamin d deficiency in coronary artery disease

Conditions: Coronary Disease

Summary: large population cross sectional study, was conducted between 2018-2020 by attendance of 4526 patients in shiraz, iran. patients were undergone selective coronary angiography from radial artery approach by an expert interventional cardiologist. 25-hydroxy vitamin d and hs-crp levels were measured for all patients

this cross-sectional study was conducted in shiraz. clinical data were collected from the patients of professor kojuri cardiovascular clinic in shiraz, iran ( iran, fars province, shiraz, niayesh boulevard, email: kojurij@yahoo.com, webpage: http://kojuriclinic.com/ )who came to clinic from march 2018 to march 2020. inclusion criteria was all of the new patients who referred to professor kojuri cardiovascular clinic. exclusion criteria were patients with more than 100ng/ml 25-hydroxy vitamin d3 serum level, parathyroid disorders, end-stage-renal-disease (esrd) and paraneoplastic syndromes. patients with more than 10mg/l hs-crp serum level also were excluded. complete history and physical exam were taken from the patients and risk factors such as hypertension, diabetes mellitus, age and gender were considered. 25-hydroxy vitamin d3 was checked for all patients. blood pressure and took electrocardiography (ecg) for all patients were done. the dependent variable was the prevalence of coronary artery disease; the independent variable was vitamin d deficiency; and intervening factors were age, gender, hypertension, diabetes mellitus and level of hs-crp. all patients were undergone selective coronary angiography from radial artery approach by an expert interventional cardiologist. angiography videos were reviewed by a team of expert cardiologists. based on the results of coronary angiography, patients were classified as non-significant cad with stenosis less than 50% and significant cad with stenosis more than 50% stenosis. in this review diabetic and hypertensive patients is considered by criteria of american diabetes association 2018 \& american heart association 2017 . patient's serum level of 25-hydroxy vitamin d on their first visit was considered as index of vitamin d level. vitamin d deficiency and sufficiency are defined respectively as serum level of 25-hydroxy vitamin d less than 30ng/ml and serum level of 25-hydroxy vitamin d more than 30 ng/ml . patients with parathyroid disorders and paraneoplastic syndromes were excluded

Eligibility criteria:
inclusion criteria: * patients with suspected coronary artery disease who referred for coronary angiography exclusion criteria: * patients with vitamin d more than 100ng/ml * parathyroid disorders * end-stage-renal-disease (esrd) * paraneoplastic syndromes * patients with more than 10mg/l hs-crp

Keywords: coronary artery disease vitamin d deficiency hs-crp
pharmacogenetic studies on anti-il-6 receptor monoclonal antibodies on the treatment of rheumatic diseases

Conditions: Rheumatoid Arthritis; Idiopathic Juvenile Arthritis; Giant Cell Arteritis; Still Disease

Summary: tocilizumab and sarilumab are first-line biological disease-modifying anti-rheumatic drug (bdmard) which inhibits interleukin 6 (il-6) pathway through blockade of its receptor on the treatment of rheumatoid arthritis and other rheumatic diseases as giant cell arteritis, still's disease and idiopathic juvenile arthritis. at present, there is a lack of evidence to recommend the treatment of one bdmard over another. seeking for genetic biomarkers to predict response to treatment could be key towards a personalized treatment strategy in rheumatology. the investigators aime to evaluate whether functional single nucleotide polymorphisms (snps) in the il6r gene could predict response and/or toxicity in patients with rheumatic diseases treated with anti-il-6 receptor drugs.


Eligibility criteria:
inclusion criteria: * diagnosis of rheumatoid arthritis by the american college of rheumatology (acr) 2010 criteria or * diagnosis of giant cell arteritis by the international league of associations for rheumatology (ilar) criteria or * diagnosis of still disease by classification criteria (yamaguchi et al.) or * diagnosis of idiopathic juvenile arthritis by acr 1990 criteria. * all of the previous must have been treated with anti-il-6r monoclonal antibodies in the last 5 years exclusion criteria: * \<18 years at recruitment * another rheumatic disease different of the ones in the inclusion criteria
hemcon© bandage for postpartum bleeding due to the multiple vaginal lacerations

Conditions: Postpartum Bleeding; Vaginal Lacerations; Cervical Lacerations

Summary: the objective of the study is to assess the safety and efficacy of the hemcon guardacarexr compared to standard bandaging in subjects with post partum hemorrhage as a result of cervical and vaginal lacerations. the primary endpoint will be a cessation of bleeding at 30 minutes after insertion of the dressing.


Eligibility criteria:
inclusion criteria: 1. signed informed consent 2. age≥18 year 3. two or more 2nd degree vaginal lacerations , 3rd degree vaginal lacerations and cervical laceration exclusion criteria: 1. subjects undertaking anticoagulation treatment 2. pre-existing coagulopathy 3. massive uncontrolled bleeding requiring blood transfusions/urgent vascular surgery. 4. systolic blood pressure \<90mmhg 5. shellfish allergy

Keywords: postpartum women, after surgical repair of vaginal and cervical lacerations
bromocriptine in the treatment of peripartum cardiomyopathy

Conditions: Peripartum Cardiomyopathy

Summary: peripartum cardiomyopathy (ppcm) is a rare, but significant heart disease affecting young women in the puerperal period. thus far, no specific treatment has been approved to treat this disease. ppcm has a wide spectrum of clinical manifestations ranging from mild heart failure to severe cardiomyopathy, cardiogenic shock and death. a significant proportion of survivors have persistent chronic heart failure leading to disabling symptoms and decreased quality of life. animal studies have suggested that prolactin is central to the development of ppcm. prolactin has pro-inflammatory and anti-angiogenic effects that may promote ppcm. bromocriptine, a central dopamine agonist known to decrease prolactin levels, might thwart its deleterious effects in women suffering from ppcm. following this rationale, bromocriptine should improve myocardial function in women suffering from ppcm and thus, improve cardiovascular outcomes and healthcare outcomes.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years; 2. peripartum cardiomyopathy defined by the following criteria: * development of heart failure in the last month of pregnancy or within 5 months of delivery; * absence of an identifiable alternative cause of heart failure; * absence of recognizable heart disease prior to the last month of pregnancy; * left ventricular systolic dysfunction demonstrated by classic echocardiographic criteria, such as depressed ejection fraction; 3. recent onset of ppcm ( 1 month); 4. written informed consent. exclusion criteria: 1. hypersensitivity or contraindication to bromocriptine; 2. patients already taking bromocriptine for ppcm or for another indication; 3. cardiogenic shock before enrolment; 4. survival expected to be less than 1 year due to non-cardiovascular causes (eg. cancer); 5. participation to another investigational drug or investigational device study within 30 days prior to randomization (participation to registries is allowed); 6. patients who in the opinion of the investigator will not comply with specified drugs, or follow-up evaluation.

Keywords: ppcm bromocriptine peripartum cardiomyopathy
comparison of effects of peep levels on respiratory mechanics in patients undergoing laparoscopic cholecystectomy

Conditions: Respiratory System Abnormalities

Summary: laparoscopic cholecystectomy is accepted as gold standard in the management of cholelithiasis. although laparoscopic procedures have many advantages,intra-abdominal co2 insufflation can cause decreased lung volumes and compliance, increased airway resistance and impaired ventilation-perfusion ratio. in this study, investigators aim to investigate effects of intra-operative peep treatment at 3 distinct levels on respiratory dynamics and elimination time of volatile anesthetic agent.

in the study, 75 asa i-ii patients aged 30-65 years will be randomized into 3 groups to receive 0 cmh2o peep (group-1), 5 cmh2o peep (group-2) and 8 cmh2o peep (group-3) in pvc mode. in all patients underwent general anesthesia; hemodynamic parameters, ppeak, pplateau, compliance values as well as fisevo/fexpsevo ratio at 1 mac and times from 1 mac to 0.3 and 0.1 mac will be recorded. in addition, preoperative and postoperative pulmonary function tests will be compared in all patients.

Eligibility criteria:
inclusion criteria: * asa (american society of anesthesiologists) i-ii * bmi of 25-30 * patients scheduled to elective laparoscopic cholecystectomy. exclusion criteria: * patients with asa iii, iv, v risk, * patients with comorbid diseases that may increase intra-abdominal pressure or pulmonary hypertension, * patients with renal and hepatic failure, * patients with pregnancy and * patients using bronchodilator or steroid were excluded.

Keywords: peep compliance peak airway pressures
precision clinical and genetic tools for brain health in hemorrhagic stroke

Conditions: Hemorrhagic Stroke

Summary: the overall goal of this study is to increase health care provider awareness for common risk factors and comorbidities in patients with hemorrhagic stroke that are related to impaired brain health, to ultimately improve patients management and associated outcomes. the specific objective is to test the performance and effectiveness of a custom electronic health record (ehr)-based notification module at time of index hospitalization and at follow-up for hemorrhagic stroke survivors, before disparities in access to outpatient care may limit opportunities to intervene. the investigators hypothesize that notification of health care providers through the ehr will increase measurements of low-density lipoprotein (ldl) and glycated hemoglogbin a1c (hba1c) and increase evaluation and management rates for obstructive sleep apnea and hearing impairment.


Eligibility criteria:
inclusion criteria: * patients aged 18 years or older * presenting with a primary diagnosis of hemorrhagic stroke admitted to massachusetts general hospital inpatient stroke service exclusion criteria: * patients not meeting above inclusion criteria * patients presenting with subdural or epidural hematoma